Scientists at Boston Children’s Hospital demonstrate that engineered telomerase RNA (eTERC) with a specialized 5' cap and 3' protective methyladenosine tail significantly enhances telomere maintenance and lifespan of induced pluripotent stem cells from patients with telomere biology disorders. Using TENT4B-mediated methylation for stabilization, eTERC treatment forestalls senescence and restores telomere length, highlighting its translational promise for regenerative medicine applications.
Key points
- Design of eTERC combining a trimethylguanosine 5′ cap and TENT4B-mediated 2′-O-methyladenosine 3′ tail for RNA stabilization.
- Single transfection of eTERC restores telomerase activity and extends telomeres in TERC-null and patient-derived iPSCs, measured by TRAP and TRF assays.
- eTERC treatment forestalls cellular senescence and enhances replicative lifespan in dyskeratosis congenita iPSCs and primary CD34+ HSPCs.
Why it matters: This enzymatically stabilized telomerase RNA offers a versatile therapeutic strategy to reverse telomere attrition in degenerative telomere disorders.
Q&A
- What is the role of the 3′-O-methyladenosine tail?
- How does the trimethylguanosine cap improve RNA stability?
- Why use induced pluripotent stem cells (iPSCs)?
- What delivery challenges exist for eTERC in vivo?